Damon Race: Pleased to Share GeneVentiv’s Scientific Debut at ASGCT 2026
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”We’re pleased to share GeneVentiv’s scientific debut at ASGCT 2026.
Our CSO, Paris Margaritis, DPhil, is presenting our work on a next-generation AAV8.FVa construct, advancing a differentiated approach to restoring thrombin generation in hemophilia A patients with or without inhibitors through native hepatic expression of a regulated coagulation cofactor.
The technology presented here forms part of GeneVentiv’s growing IP portfolio.
It’s exciting to reflect on this work as the foundation for our program, which has advanced to studies in hemophilia A canines.
We look forward to sharing additional data as development progresses.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!
-
Sep 28, 2026, 19:07Dhargam Aljebouri: AIHA Subclassification Research Presented at the 14th Iraqi Society of Hematology Conference
-
Sep 28, 2026, 19:02William Wallace: Your Cholesterol Test is Missing a Particle that May Matter More than the One it Measures
-
Sep 28, 2026, 18:57Indu Thakur: Honoring Sickle Warriors and Advancing Diverse Blood Donation at Sickle Ball 2026
-
Sep 28, 2026, 18:48Orly Leiva: Rethinking JAK Inhibitor Cardiovascular Safety in MPNs
-
Sep 28, 2026, 18:42Wael Saad: Honored to Be Part of Portal and Mesenteric Vein Thrombosis Session at CIRSE 2026
-
Sep 28, 2026, 18:35Alejandro González Veliz: The Unbroken Connection Between Heart and Brain